Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Biolase Inc. (BIOL) rose 52.0% to $0.228 on volume of 76,448,685 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 8.5% to $0.1476 on volume of 32,191,096 shares Nova Lifestyle Inc (NVFY) rose 121.6% to $4.1 on volume of 32,...
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces complete clinical re...
2024-03-22 06:53:31 ET More on Matinas Biopharma Seeking Alpha’s Quant Rating on Matinas Biopharma Historical earnings data for Matinas Biopharma Financial information for Matinas Biopharma Read the full article on Seeking Alpha For further det...
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced that on March ...
A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and endemic mycoses such as coccidioidomycosis and histoplasmosis All 5 patients who completed the desired co...
ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will enroll approximately 216 patients with primary endpoint of all-cause mor...
BEDMINSTER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announce...
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute psoriasis model, data show reductions in tissue IL-17A mRNA and improvement in cli...
Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas to Meet with FDA Early in the First Quarter of 2024 to Finalize Phase 3 Study Design Partnership Discussions Remain Ongoing for MAT2203 BEDMINS...
2023-11-08 22:44:10 ET Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Conference Call November 08, 2023 04:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO ...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...
Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track Company’s strategy to expand its LNC platform into in...
BEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focu...